Doxorubicin hydrochloride
Injection, powder, lyophilized, for solution · Intravenous · Prescription
Boxed warning
- Cardiomyopathy: Myocardial damage, including acute left ventricular failure, can occur with doxorubicin hydrochloride. The risk of cardiomyopathy is proportional to the cumulative exposure with incidence rates from 1% to 20% for cumulative doses ranging from 300 mg/m2 to 500 mg/m2 when doxorubicin hydrochloride is administered every 3 weeks. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess left ventricular ejection fraction (LVEF) before and regularly during and after treatment with doxorubicin hydrochloride [see Warnings and Precautions (5.1)].
- Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin hydrochloride [see Warnings and Precautions (5.2)].
…
Uses
1.1 Adjuvant Breast Cancer
Doxorubicin hydrochloride for injection is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer.
1.2 Other Cancers
Doxorubicin hydrochloride for injection is indicated for the treatment of
- acute lymphoblastic leukemia
- acute myeloblastic leukemia
- Hodgkin lymphoma
- non-Hodgkin lymphoma (NHL)
- metastatic breast cancer
- metastatic Wilms’ tumor
- metastatic neuroblastoma
- metastatic soft tissue sarcoma
- metastatic bone sarcoma
- metastatic ovarian carcinoma
- metastatic transitional cell bladder carcinoma
- metastatic thyroid carcinoma
- metastatic gastric carcinoma
- metastatic bronchogenic carcinoma
From the FDA label of Amneal Pharmaceuticals LLC, version of May 29, 2024. Not medical advice: ask your doctor or pharmacist.
Active ingredient
- Doxorubicin hydrochloride
Generic name
- Doxorubicin
- Doxorubicin Hydrochloride
Drug class
- Anthracycline Topoisomerase Inhibitor
- Topoisomerase Inhibitors
Inactive ingredients and allergens
- Lactose: all 3 products
- Amneal Pharmaceuticals LLC, 2 mg/mL: lactose monohydrate
- Hikma Pharmaceuticals Usa Inc, 2 mg/mL: lactose monohydrate
- Mylan Institutional LLC, 2 mg/mL: lactose monohydrate
From each product's FDA label; they differ between manufacturers and strengths. The app shows every product and finds those without an allergen.
Other forms of Doxorubicin hydrochloride
Official FDA label
- Amneal Pharmaceuticals LLC on DailyMed, version of May 29, 2024
- Hikma Pharmaceuticals Usa Inc on DailyMed, version of Apr 26, 2024
- Mylan Institutional LLC on DailyMed, version of Jul 1, 2022
Read the full label as text, with its contents and search, in the app.
Data: FDA NDC Directory, DailyMed labels, Orange Book, Purple Book and Enforcement Reports, updated Nov 19, 2026.